Kestra Medical Technologies (NASDAQ:KMTS) Stock: Insider Traci Umberger Sells 100,000 Shares

Key Points

• Insider Traci Umberger sold 100,000 KMTS shares at an average price of $27.18, generating $2.718 million and reducing her holdings by 33.8% to 195,825 shares.
• Kestra Medical Technologies shares rose to $28.32, near their 52-week high of $30.00, despite reporting a quarterly EPS loss of $0.75 that missed analyst expectations by $0.14.
• Analysts maintain an overall “Moderate Buy” rating, with an average price target of $29.00, while the company continues to post significant losses and analysts project a full-year EPS loss of $2.45.

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) insider Traci Umberger sold 100,000 shares of the firm's stock in a transaction dated Wednesday, October 21st. The shares were sold at an average price of $27.18, for a total transaction of $2,718,000.00. Following the completion of the sale, the insider owned 195,825 shares of the company's stock, valued at $5,322,523.50. This trade represents a 33.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Kestra Medical Technologies Price Performance

Kestra Medical Technologies stock traded up $1.01 during mid-day trading on Thursday, reaching $28.32. The company had a trading volume of 739,134 shares, compared to its average volume of 349,841. The stock's 50-day simple moving average is $26.40 and its 200-day simple moving average is $23.73. Kestra Medical Technologies, Ltd. has a 1 year low of $17.34 and a 1 year high of $30.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.69 and a quick ratio of 4.69. The company has a market capitalization of $1.69 billion, a P/E ratio of -10.61 and a beta of 0.51.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last announced its quarterly earnings results on Monday, September 14th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.14). Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. The firm had revenue of $30.97 million for the quarter. On average, equities analysts predict that Kestra Medical Technologies, Ltd. will post -2.45 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. JPMorgan Chase & Co. initiated coverage on shares of Kestra Medical Technologies in a research report on Monday, August 10th. They set an "overweight" rating and a $30.00 target price for the company. Royal Bank Of Canada set a $30.00 price target on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Weiss Ratings raised shares of Kestra Medical Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, September 16th. Wall Street Zen downgraded Kestra Medical Technologies from a "hold" rating to a "sell" rating in a research report on Saturday, September 12th. Finally, Oppenheimer began coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a "market perform" rating on the stock. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $29.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KMTS. Quantinno Capital Management LP purchased a new stake in shares of Kestra Medical Technologies during the first quarter worth about $431,000. California State Teachers Retirement System lifted its stake in shares of Kestra Medical Technologies by 39.2% during the first quarter. California State Teachers Retirement System now owns 27,835 shares of the company's stock valued at $555,000 after buying an additional 7,844 shares during the period. Spartan Wealth Advisory Services LLC purchased a new position in shares of Kestra Medical Technologies during the first quarter valued at approximately $603,000. Corient Private Wealth LP boosted its position in Kestra Medical Technologies by 284.2% during the second quarter. Corient Private Wealth LP now owns 60,614 shares of the company's stock worth $1,542,000 after acquiring an additional 44,839 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Kestra Medical Technologies by 47.2% during the first quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company's stock worth $1,397,000 after acquiring an additional 22,471 shares during the last quarter.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient's heart rhythm and deliver a therapeutic shock when clinically necessary.

The company's platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.